<DOC>
	<DOCNO>NCT03047837</DOCNO>
	<brief_summary>Epidemiological study cardiovascular prevention trial show low-dose aspirin ( ASA ) inhibit colorectal cancer ( CRC ) incidence mortality , include inhibition distant metastasis . Metformin ( MET ) also associate decreased CRC incidence mortality meta-analyses epidemiological study diabetic show decrease 40 % colorectal adenoma recurrence randomize trial . Recent study show ASA inhibitor mTOR/S6K1 activator AMPK , target regulator intracellular energy homeostasis metabolism , combination ASA MET , another AMPK activator S6K1 inhibitor , strike additive effect AMPK activation mTOR inhibition , increase autophagy decrease cell growth CRC cell line . While drug test single agent , combination test trial . This randomized , placebo-controlled , double blind , 2x2 biomarker trial ASA MET test activity either agent alone potential synergism combination set surrogate biomarkers colorectal carcinogenesis . After surgery 160 patient stage I-III colon cancer randomly assign four-arm trial either ASA , 100 mg day , MET 850 mg bid , combination , placebo one year . The primary endpoint biomarker change , define difference pre- post-treatment expression nuclear factor kappa-B ( NFκB ) , unaffected mucosa proximal distal colon obtain multiple biopsy two pair colonoscopy one year apart . Additional biomarkers include : 1 ) genomic profile candidate gene , pathway , overall genomic pattern tissue biopsies genome wide gene expression array ; 2 ) IHC expression tissue pS6K , p53 , beta-catenin , PI3K ; 3 ) association mutation SNPs treatment response next generation sequence primary tumor ; 4 ) measurement circulate IL-6 , CRP VEGF 5 ) plasma colonic MET concentration correlation biomarker profile .</brief_summary>
	<brief_title>A Randomized , 2x2 Factorial Design Biomarker Prevention Trial Low-dose Aspirin Metformin Stage I-III Colorectal Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patients age &gt; 18 ≤ 80 year . Patients completely resect stage I , II , III primary colorectal cancer within 24 month prior randomization , regardless ( neo ) adjuvant chemotherapy . Patients pT1 CRC treat endoscopic polypectomy . Adjuvant chemotherapy ( neo ) adjuvant radiotherapy terminate least 3 month randomization . ECOG performance status ≤ 1 . Satisfactory hematological biochemical function : Platelets ≥ 100 x 10^9/L Creatinine clearance estimate Cockcroft Gault formula ≥ 60 mL/min . Patients Gault formula ≥ 4559 ≤ ml/min eligible receive single ( even ) tablet MET , 850 mg. AST ALT ≤ 2.5 time ULN . Females childbearing potential/males partner childbearing potential participating study use effective method birth control study participation . Female participant must provide pregnancy test , accord local/national guideline . Able understand sign inform consent ( legal representative able willing ) . Patients able undergo colonoscopy . Patients allergic intolerant ibuprofen naproxen , MET , ASA , salicylate intolerance generalize drug intolerance nonsteroidal antiinflammatory drug ( NSAIDs ) . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent patient sign participate study and/or comply study procedure . Chronic treatment ASA NSAIDs MET patient current long term treatment ( ≥ 4 consecutive week ) ASA , NSAID COX 2 inhibitor MET . Diabetic patient drug treatment exclude . Anticoagulant therapy ( dicumarol , heparin , fondaparinux , apixaban , dabigatran etexilate , rivaroxaban ) active current treatment antiplatelet agent ( e.g . offstudy ASA , clopidogrel , prasugrel , ticagrelor , ticlopidine ) . Any invasive malignancy ( exclusion basal cell carcinoma cutaneous squamous cell carcinoma ) diagnose last 5 year randomization . Past history invasive CRC one patient currently treat Alcohol drug abuse . Prior history gastrointestinal bleeding hemorrhagic diathesis ( e.g . hemophilia ) . Erosiveulcerative lesion gastrointestinal tract . History erosive GERD active erosive GERD gastroscopy . Concomitant corticosteroid treatment . Known deficiency glucose6phosphate dehydrogenase ( G6PD ) . Treatment another investigational drug &lt; 28 day prior study entry . Concurrent participation clinical trial endpoint . History hemorrhagic stroke . Lynch Syndrome ( HNPCC ) . Crohn 's disease ( CD ) Ulcerative Colitis ( UC ) . Pregnant lactating female . History lactic acidosis . Liver dysfunction include chronic active hepatitis cirrhosis compensate . History vitamin B12 deficiency megaloblastic anemia . Uncontrolled coronary syndrome symptomatic congestive heart failure ( e.g . Class III IV New York Heart Association 's Functional Classification ) . Inability unwillingness swallow tablet .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>aspirin</keyword>
	<keyword>metformin</keyword>
	<keyword>chemoprevention</keyword>
</DOC>